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Objectives: Positron emission tomography (PET)/CT with 18F-FDG has proven to be effec-
tive in detecting and assessing various types of cancers. However, due to cancer and/or
its therapy, intravenous (IV) FDG injection may be problematic resulting in dose extravasa-
tions. In the most frequently used ﬁeld of view (FOV), arms-up, and base of skull to upper
thigh [limited whole body (LWB)], the injection site may not be routinely imaged. The pur-
pose of this study was to evaluate the frequency of dose extravasations in FDG PET and
the potential impact on standard uptake value (SUV) measurements.Methods:True whole
body FDG PET/CT scans (including all extremities) of 400 patients were retrospectively
reviewed. A log recorded cases of IV dose extravasations. When possible, SUVs were
measured in two frequently used reference locations: mediastinum and liver. The SUVs
were obtained in the same patients who had studies with and without FDG extravasations
within an average of 3months without interval therapy. Results: Of the 400 scans, 42
(10.5%) had extravasations on the maximum intensity projections images. In scans with or
without dose inﬁltration, FDG injection site was at or distal to the antecubital fossa in 97%
of studies. Of those 42 cases, dose inﬁltration was within the LWB FOV in 29/42 (69%) and
outside in the remaining 13/42 (31%). Of those 42 patients, 5 had repeat PET studies with
no interval therapy. For those 5 patients, liver maximum SUV was 11.7% less in patients
with inﬁltration than those without (2.22± 0.54 vs. 2.48± 0.6). Mediastinum SUVmax was
9.3% less in patients with inﬁltration than those without (1.72± 0.54 vs. 1.88± 0.49).
Conclusion: We conclude dose extravasations were commonly encountered (10.5%) in
PET/CT. However, it is underreported by at least 31% due to omitting injection site from
the FOV. When present, extravasations may lead to underestimation of SUVmax. There-
fore, it should not only be avoided but also reported in order to avoid false interpretations
of the exam.
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INTRODUCTION
Positron emission tomography (PET) using ﬂuorine-18-2-deoxy-
d-glucose (18F-FDG) diagnoses, stages, and restages many cancers
with an accuracy ranging from 80 to 90% and is often better than
anatomical imaging (Czernin et al., 2007). Since the introduc-
tion of PET/CT, numerous studies showed that this whole body
(WB) dual-modality imaging is better than PET or CT alone
for staging and restaging most cancers (Czernin et al., 2007).
Consequently, by 2006, the major vendors no longer offered PET-
only systems, and by 2010, over 5000 combined PET/CT systems
were in clinical operation worldwide (Mawlawi and Townsend,
2009; International Survey of PET/CT Operations and Oncology
Imaging, 2010). The improvement in accuracy coupled with the
convenience of presenting anatomical and functional information
to physicians has rendered PET/CT imaging as the most impor-
tant cancer imaging modality at the present time (Bar-Shalom
et al., 2003). Furthermore, the use of PET/CT has been advocated
as a ﬁrst-line imaging modality for WB tumor staging, restaging,
and assessing response to therapy in different types of neoplasm
(Antoch et al., 2003).
In oncology,WB PET/CT is typically performed from the head
to the pelvic ﬂoor (Von Schulthess et al., 2006). The use of the
term WB is misleading since the most commonly used ﬁeld of
view (FOV) for the arms-up PET/CT WB protocol only includes
the base of skull to upper thighs, thus limitedWB (LWB), and does
not include the brain, skull, and signiﬁcant portions of both upper
and lower extremities. In addition, the arms of patients undergo-
ing PET/CT for cancer evaluation should be extended over the
head except in head and neck cancers in which arms should be
positioned along the sides (Delbeke et al., 2006). Therefore, the
most commonly used injection site, the antecubital fossa, is fre-
quently not included in the imaged FOV. Furthermore, due to
cancer and/or its therapy, intravenous (IV) FDG injection may
be problematic and occasionally result in dose extravasations. In a
previous clinical study from this same site, truewhole body (TWB)
image acquisition, from the top of the skull to the bottom of the
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feet, revealed the presence of new, previously unidentiﬁed malig-
nant sites outside the typical LWB FOV in 4% of patients (Osman
et al., 2010). Consequently, we use TWB as the standard of care in
all our cancer patients. In so doing, the injection site, with or with-
out dose inﬁltration, is always included in the imaged FOV. The
objective of the current study was to evaluate the frequency and
pattern of dose extravasations in FDG PET and, when possible,
to investigate potential impact of such extravasations on standard
uptake value (SUV) measurements.
MATERIALS AND METHODS
PATIENTS
A total of 400 consecutive PET/CT scans for patients referred for
clinical evaluation of known or suspected malignancy between
May 2006 and October 2006 were retrospectively evaluated for the
presence of FDG extravasations at the injection site. All IV injec-
tions were performed by three experienced technologists (Certi-
ﬁed Nuclear Medicine Technologist and PET certiﬁed) injecting
>1800 cases/year. This retrospective study was approved by the
Institutional Review Board and the need for informed consent
was waived.
PET INJECTION TECHNIQUE
The standard F-18 FDG intravenous injection in our facility was
performed using a 23 or 25 gage butterﬂy needle. The needle was
inserted into a vein and connected to a three-way stopcock. The
stopcock had saline and an empty 3ml syringe attached. After
placing the needle into the vein, the technologist drew blood into
the empty 3ml syringe. This blood was used to check the patient’s
blood glucose level. The technologist then ﬂushed the line with the
saline attached to the stopcock. After the blood glucose level was
checked and within the acceptable range, the technologist mea-
sured the FDG activity in the dose calibrator and brought the
dose into the injection room. The technologist unscrewed the 3-
ml blood syringe from the stopcock and attached the FDG dose.
The activity was injected through the butterﬂy needle and ﬂushed
with 10–20ml saline. After FGD injection and saline ﬂush, the
butterﬂy needle was removed from the patient. The injection site
was covered with gauze and tape to stop bleeding at the site. The
technologist then performed a post-injection measure of the dose
syringe to calculate the net injected dose.
PET/CT SCANNING
Patients fasted at least 4 h before the PET acquisition and
received an intravenous injection of approximately 5.18MBq/Kg
(0.14mCi/Kg) of 18F-FDG, with a maximum of 444MBq
(12mCi). Blood glucose level was measured immediately prior
to FDG injection and was <200mg/dl in all patients. Patients
were instructed to sit in a quiet injection room without talking
during the subsequent 60min of the FDG uptake phase and were
allowed tobreathenormally during image acquisitionwithout spe-
ciﬁc instructions. All scans were acquired using a PET/CT scanner
(Gemini; Philips Medical Systems), with an axial co-scan range of
193 cm.
CT SCANNING
The CT scan component of the PET/CT scanner consisted of a 16
slice multidetector helical CT. Gantry allows for a patient port of
70 cm.Parameterswere as follows for 12–13bed acquisitions (from
the top of the head through the bottom of the feet): 120–140KV
and33–100mAs (basedonbodymass index),0.5 s perCT rotation,
pitch of 0.9 and 512× 512 matrix. CT acquisition was performed
before emission acquisition. CT data were used for image fusion
and the generation of the CT transmission map. In all patients,
the arms were placed above the patient’s head for CT acquisition
except in patients with head and neck cancers where the arms were
placed at the patient’s sides. The CT images were obtained without
oral or IV contrast according to the usual PET/CT protocol in our
institution.
PET SCANNING AND IMAGE PROCESSING
The PET component of the PET/CT scanner was composed of
gadolinium oxyorthosilicate (GSO)-based crystals. Emission data
were acquired for 12–13 bed positions (193 cm coverage, identical
to the CT protocol). Emission scans were acquired at 3min per
bed position. The FOVwas from the top of the head to the bottom
of the feet in all patients. The three-dimensional (3D) TWB acqui-
sition parameters consisted of a 128× 128 matrix and an 18-cm
FOVwith a 50%overlap. Processing consisted of the 3D rowaction
maximum likelihood algorithm (RAMLA) method (Browne and
De Pierro, 1996). Total scan time per patient was 36–39min.
IMAGE ANALYSIS
For each of the 400 patients included in this study, PET/CT reports
were reviewed for the reported injection site. TWB static maxi-
mum intensity projection (MIP) PET images were retrospectively
evaluated on Syntegraworkstations (PhilipsMedical Systems), and
a log was kept to record cases of FDG dose extravasations at the
injection site and this was compared to the injection site docu-
mented in the PET/CT report. A dose was considered extravasated
if any remaining FDG activity was visible at the site of injection
within the body. In addition, a note wasmade of the location of the
injection site. Dose extravasations cases were categorized into two
groups; thosewithin the routinely used base of skull to upper thigh
(LWB) FOV and those with extravasations occurring outside the
typical LWB, i.e., can only be detected by TWB image acquisition.
SUV MEASUREMENTS
Five patients had repeat PET studies within an average of
3months without interval therapy for close follow-up. Each
patient had a study both with and without FDG extravasation.
In an attempt to evaluate potential impact of dose extravasations
on quantitative measurements, maximum SUVs were measured
(ROI= 500mm2) in two frequently used anatomical reference
locations: liver (mid right lobe) andmediastinumblood pool (aor-
tic arch). For those cases, all available data was compared to select
patients who had normal, almost similar, blood glucose levels in
both studies and had no weight changes between studies. Image
acquisition parameters were kept the same in all studies.
This retrospective study was approved by the Institutional
Review Board and the need for informed consent was waived.
RESULTS
Of 400 PET/CT scans, FDG injection was performed at or distal to
the antecubital fossa in 388 (97%) of reviewed reports. Of those
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400 scans, 42 (10.5%) had extravasations noticeable on the MIP
images. Of those 42 cases, 29 (69%) of the extravasations were
noted within the LWB (Figure 1) whereas the remaining 13 (31%)
were outside the LWB imaged FOV (Figure 2). Of the 42 studies
with dose extravasations, injection site included: the right antecu-
bital fossa in 17 (40%), the left antecubital fossa in 12 (29%), the
right wrist 7 (17%), the left wrist in 3 (7%), chest chemotherapy
port was used for FDG injection in 2 (5%) cases and injection was
done in the right neck in a single case (2%).
FIGURE 1 | Maximum intensity projection (MIP) PET image of a
63-year-old male with a history of esophageal cancer. Patient was
injected in the left antecubital fossa (LAC) with dose extravasation (SUVmax
196) within the LWB FOV.
Of those 42 patients, 10 had repeat PET studies with and with-
out tracer inﬁltration within the observation period. Of those 10,
only 5 had no interval therapy with almost similar blood glucose
level and no weight changes between the scans. Therefore, those 5
met inclusion criteria and were selected for ROI analysis and SUV
measurements. Mean liver SUV max was 11.7% less in patients
with inﬁltration than those without (2.22± 0.54 vs. 2.48± 0.6)
and mean mediastinal SUV max was 9.3% less in patients with
inﬁltration than those without (1.72± 0.54 vs. 1.88± 0.49). An
example is presented in Figure 3.
DISCUSSION
The National Oncologic PET Registry (NOPR) evaluated 40,863
PET studies done at 1368 centers and concluded that FDG PET
changed management for 38% of cases (95% conﬁdence inter-
val= 37.6–38.5%) across cancer types, providing strong evidence
FIGURE 2 | MIP PET image of an 83-year-old female with metastatic
disease from an unknown primary. Patient was injected in the right
antecubital fossa (RAC) with dose extravasation (SUVmax 7) outside the
LWB FOV (right).
www.frontiersin.org November 2011 | Volume 1 | Article 41 | 3
Osman et al. FDG dose extravasations in PET/CT
FIGURE 3 | Patient is a 46-year-old male with a history of melanoma. Left MIP shows extravasation in the right wrist and a repeat PET was performed
5months later with no extravasation. The top row shows SUV measurement of the mediastinum with extravasation and the second row shows SUV of the
mediastinum without extravasation. The third row shows SUV of the liver with extravasation and the bottom row shows SUV of the liver without extravasation.
that FDG PET is useful for many types of cancer and indica-
tions beyond those currently reimbursed by Centers for Medicade
and Medicare Services (CMS; Hillner et al., 2008). In addition,
FDG PET is currently plays a growingly critical role in assessing
response to therapy in several tumor types. A relatively recent
analysis of the NOPR data showed that 19% of the registered
scans were performed for treatment monitoring (Hilner et al.,
2008). A recent follow-up publication concluded that essential
elements that should be included in oncologic PET reports were
missing. Therefore,many reports are less helpful to referringphysi-
cians, may lead to misdiagnosis, and may cause coding and billing
errors (Coleman et al., 2010). According to the same study, FOV
scanned and route of FDG administration were absent from the
PET/CT reports evaluated by NOPR in 8.4 and 31%, respectively.
Further, this study did not evaluate location of injection site, in
terms of being in or out the imaged FOV, the presence of FDG
dose extravasations and potential impact of such extravasations on
SUV measurements. Such data would be difﬁcult to obtain in the
most commonly used scanned FOV, base of skull to upper thigh,
because the injection site is typically outside the FOV. In clini-
cal practice, visual inspection of PET images is the main tool for
image interpretation.However, the reading physicianwould not be
able to incorporate the presence of dose inﬁltration and potential
impact on the degree of metabolic activity if injection site was not
included in the imaged FOV. In this study, 400 PET/CT scans were
reviewed and extravasation was noted in 42 cases (10.5%). Of the
42 cases with extravasations, dose inﬁltration was within the LWB
FOV in 29 (69%) and outside in the remaining 13 (31%). Since
the antecubital fossa is the most common site of injection, many
of such cases would be outside the LWB FOV except in head and
neck cases where the arms are at the patient’s side as the standard
protocol.
Since 1993 when quantitative F-18 FDG PET was introduced
for the early sequential monitoring of tumor response, there has
been a growing interest in using FDG PET in assessing response
to therapy (Wahl et al., 1993). Of the many different ways to
monitor tumor response, SUV is the most widely applied and
generally correlates well with more complex analytic approaches
(Graham et al., 2000; Krak et al., 2003). To achieve reproducible
SUV measurements, absolute and rigorous standardization of the
protocol for PET image acquisition is required. On one hand, an
SUV drop of more than 20% is considered a response on the
basis of reproducibility considerations (Weber, 2005). According
to the EORTC, 15% decline in SUV is considered response (Young
et al., 1999). On the other hand, in a test–retest setting, the repro-
ducibility of SUV measurements has varied. Boellards recently
reported that variation in camera calibration, image reconstruc-
tion, and data analysis and/or settings can have more than a
50% effect on the measured SUV (Bollaard, 2009). The same
publication reported that the effect of paravenous administra-
tion of FDG on SUV measurements is in the range of 0–50%
or more, strongly depending on quality of administration. How-
ever, this was reported as estimated values based on unpublished
data.
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FIGURE 4 | Maximum intensity projections PET image (LWB FOV) of a
patient with a history of lung cancer. Dose extravasation in the LAC at
the edge of the image ﬁeld with SUVmax 1297.
Comparing tumor activity to an internal reference point such
as liver and mediastinal blood pool is an attractive way to
minimize variability and to potentially ensure quality of scan
from test to retest (Paquet et al., 2004). In our study, how-
ever, mean liver SUV max was 11.7% less in patients with
inﬁltration than those without (2.22± 0.54 vs. 2.48± 0.6) and
mean mediastinal SUV max was 9.3% less in patients with inﬁl-
tration than those without (1.72± 0.54 vs. 1.88± 0.49). There-
fore, the presence of extravasations may potentially affect not
only accuracy but also reproducibility of SUV measurements.
In such cases, assessing response to therapy may become more
challenging.
The presence of extravasation alone, however, may not be the
only factor on affecting SUV measurements. The intensity of the
extravasationmay have greater affect than the size alone. A visually
small site of extravasation with high SUV has more impact on
accuracy and reproducibility of SUV measurements than a larger
site with a lower SUV. For example, Figure 4 shows extravasation
at the edge of the ﬁeld with SUVmax 1297. Figure 1 shows a visu-
ally larger amount of extravasation but a SUVmax of only 196.
Although the amount of extravasation visually looks different, the
ﬁrst patient has a high concentration of radioactivity as seen by
the intense SUV and has a more profound impact than the second
patient.
Our study is not without limitations. The retrospective nature
of the study is a potential limitation. Also, the prevalence of
extravasation may be underestimated in our study due to the high
number of head and neck cases in our institution requiring the
arms at the patient’s side. Furthermore, the SUV at the site of
extravasation was not calculated in all 42 patients. In addition, our
study could not adequately assess the impact of the extravasation
on the lesion’s SUV due to the small sample size. Future studies
can better assess the clinical impact of dose extravasation by quan-
tifying the intensity of extravasation and comparing it with the
lesion SUV in a larger sample size. Furthermore, the site of injec-
tion should be included in clinical practice when possible, but it
becomes more important in clinical trials when uptake values are
needed for consistency.
CONCLUSION
We conclude that dose extravasation is commonly encountered
(10.5%) in PET/CT. However, it is underreported due to omitting
injection site from the FOV. When present, extravasations lead to
underestimation of SUVmax by an average of 11.7% in liver and
9.3% in mediastinum. Extravasations should not only be avoided
but also reported in order to avoid false interpretations of the
PET/CT exam.
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